// App-Quantinova.ai

511 : Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors – Results from the Phase II Study

Researchers

Presenter

  • Steven W. Pipe

Principal Investigators

  • John Pasi

  • Toshko Lissitchkov

  • Margaret V. Ragni

  • Claude Ngrier

  • Qifeng Yu

  • Stacey Poloskey

  • Baisong Mei

  • Shauna R. Andersson

Medical Centers

  • Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI

  • Royal London Haemophilia Centre, Barts and the London School of Medicine and Dentistry, London, United Kingdom

  • Department of Chemotherapy, Hemotherapy, and Hereditary Blood Diseases, Specialized Hospital for Active Treatment of Hematological Diseases, Sofia

  • Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

  • Hôpital Cardiologique Louis Pradel, Lyon, France

  • Albireo Pharma, Boston, MA

  • Sanofi, Waltham, MA.

  • Sanofi, Cambridge, MA

Locations

  • United States

  • United Kingdom

  • Bulgaria

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • NCT02035605

  • NCT02554773

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved